cancer
Conditions
Interventions
Test Group:Apatinib, 250 mg po, qd, Local radiotherapy
Control Group:zoledronic acid: 4 mg, iv, Every 4 weeks
Sponsors
Da Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 Years to 75 Years men and women; 2. Patients must have histologically confirmed Solid tumor patients (including the stomach or gastroesophageal junction, non squamous adenocarcinoma non-small cell lung cancer, breast cancer, hepatocellular carcinoma (HCC) or other types of solid tumor); 3. Imaging examination confirmed that at least one bone metastatic lesions; 4. ECOG PS0-2 points; 5. Life expectancy =3 months; 6. With normal marrow, liver and renal function; 1) blood routine examination (without blood transfusion during 14 days), HB=90g/L, ANC =1.5×10^9/L, PLT =80×10^9/L; b) Biochemical examination:a total bilirubin (TBil) of =1.5 upper normal limitation (UNL); alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of =2.5 UNL or =5 UNL in case of liver metastasis.creatinine (Cr) of = 1 UNL; a creatinine clearance rate = 50ml/min (Cockcroft-Gault); 7. With written informed consent signed voluntarily by patients themselves; 8. With good compliance and agree to accept follow-up of disease progression and adverse events.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension (after treatment with antihypertensive drugs cannot reduced to the normal range; 2. Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction); 3. With potential bleeding risk including: (1) peptic ulcer and fecal occult blood (++); (2) melena or hematemesis history in last 3 months; (3) fecal occult blood (+) or (+/-) and endoscopy showed ulcer or other diseases with bleeding risk; 4. With abnormal coagulation function (INR>1.5 ULN, APTT>1.5 ULN); 5. Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening; 6. Uncontrolled infection; 7. Pregnant or lactated women; . 8. Other conditions regimented at investigators' discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of bone related events; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS;safety; | — |
Countries
China
Contacts
Public ContactZhong Zhaoyang
Daping Hospital
Outcome results
None listed